Chelsie Derman

A recent study showed expression profiles of amacrine cells, the interneurons within the retina, were enriched in schizophrenia genetic risk factors.

Individuals with stable schizophrenia struggle to recognize facial emotions such as sadness, disgust, and anger—but not happiness—which may impact social interactions.

A study found long-acting injectables reduced mean Young Mania Rating Scales scores in adolescents with bipolar mania from 33.8 at baseline to 21.7 at month 1.

Phase 2 data demonstrates the effectiveness of LB-102, developed with the potential to be the first-in-class benzamide antipsychotic, for adults with acute schizophrenia.

This Month in Review captures 7 sleep medicine news, including FDA updates, from December 2024.

A study found intimate partner violence significantly lowers women's psychosocial well-being across finances, health, and relationships, but not men's.

Participants with greater vitamin D levels had a 16% lower migraine prevalence than those with lower vitamin D levels.

Glutamatergic medications show promise for OCD & related disorders, reducing Y-BOCS scores.

A study found that the protein ADM significantly mediates loneliness' link to cardiovascular disease, stroke, dementia, and mortality, emphasizing loneliness’ health risks.

A recent study found individuals released from incarnation had a 10-fold greater prevalence of suicide mortality compared with the general population.

This Psychiatry Month in Review features promising phase 3 data, what is moving in the pipeline, and where the psychiatry field is heading into 2025.

A study found that NT-proBNP levels predict cardiovascular and renal risks in patients with advanced CKD and anemia. Greater NT-proBNP variability showed increased renal risks.

Although the oral navacaprant 80 mg failed to bring statistically significant improvements in depression symptoms, the study showed females respond better than males.

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

From FDA approvals to updated guidelines, 2024 brought transformative advancements in sleep medicine, offering new hope for managing complex sleep disorders.

Atogepant 60 mg, an oral CGRP receptor antagonist, demonstrated rapid and effective migraine prevention, reducing frequency and improving function in 4 weeks.

A study shows that a lower non-HDL/HDL cholesterol ratio is linked to greater anemia prevalence. A threshold of 4.28 shows a 15% anemia risk drop per unit increase below this value.

MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.

A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.

A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.

A phase 3 trial shows promising data for brexpiprazole with sertraline for PTSD symptoms ahead of the supplemental new drug application’s PDUFA date in February 2024.

In a recent study, tralokinumab demonstrates effectiveness and safety for treating moderate-to-severe atopic dermatitis in adults who are dupilumab naïve and non-naïve.

A study showed parents of children with atopic dermatitis have an increased odds of taking medication to aid sleep.

A study shows young adults with negative emotionality, particularly alienation, who experienced childhood adversities often experience more stressful life events in adulthood.

In a recent study, the prevalence of RLS occurred in 42.9% of participants with depression.

Efficacy and safety of brilaroxazine for schizophrenia sustained for > 1 year in open-label extension of RECOVER, announced by Reviva Pharmaceuticals.

A study finds that therapists deliver high-quality CBT in routine psychiatric care but found no evidence that therapist adherence and competence correlate to patient outcomes.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

Patients with schizophrenia and COVID-19 both present dysregulated energy metabolism, explaining the high COVID-19 rates among those with schizophrenia.